EcoDrugPlus

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSSVLG00005018715
Gene Symbol: CHRM2
1 Cross references
259 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSVLG00005017086
Gene Symbol: CHRM3
1 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSVLG00005015740
Gene Symbol: CHRM4
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSSVLG00005001848
Gene Symbol: CHRM5
1 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSVLG00005006641
Gene Symbol: CHRNA3
1 Cross references
207 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSSVLG00005004453
Gene Symbol: CHRNA4
1 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSVLG00005014638
Gene Symbol: CHRNB2
1 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSVLG00005006614
Gene Symbol: CHRNB4
1 Cross references
198 Possible Orthologues:

Chymase 1

Ensembl ID : ENSSVLG00005005032
Gene Symbol: CMA1
1 Cross references
292 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSVLG00005008506
Gene Symbol: F2R
1 Cross references
327 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSSVLG00005014116
Gene Symbol: F2
1 Cross references
85 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSSVLG00005001139
Gene Symbol: F3
1 Cross references
243 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).